0.55%
1.03%
-6.96%
-20.91%
55.76%
473.27%
200.70%
AI Spotlight on ZEAL
Company Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon.
The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism.The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome.Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc.
The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Market Data
| Last Price | 735.5 |
| Change Percentage | 0.55% |
| Open | 737 |
| Previous Close | 731.5 |
| Market Cap ( Millions) | 51961 |
| Volume | 105259 |
| Year High | 972 |
| Year Low | 431 |
| M A 50 | 736.7 |
| M A 200 | 779.61 |
Financial Ratios
| FCF Yield | -1.37% |
| Dividend Yield | 0.00% |
| ROE | -18.54% |
| Debt / Equity | 4.38% |
| Net Debt / EBIDTA | 12.25% |
| Price To Book | 5.85 |
| Price Earnings Ratio | -49.38 |
| Price To FCF | -73.04 |
| Price To sales | 675.96 |
| EV / EBITDA | -52.26 |
News
- Jan -13 - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Jan -09 - High Growth Tech Stocks to Watch in January 2025
- Jan -07 - Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
- Jan -06 - Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
- Dec -25 - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Dec -25 - Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
- Dec -23 - Hot Obesity Drug Market Will Keep Investors Gripped Next Year
- Dec -19 - U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
- Dec -15 - 2 Weight Loss Stocks That Are Screaming Buys in December
- Dec -11 - Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement
- Dec -10 - Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
- Nov -13 - Zealand Pharma to participate in the Jefferies London Healthcare Conference
- Nov -12 - Exploring High Growth Tech Stocks In November 2024
- Nov -11 - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
- Nov -08 - Zealand Pharma Gains as JPMorgan Flags $10 Billion Opportunity
- Nov -08 - Zealand Pharma AS (ZLDPF) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Financial ...
- Nov -07 - Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
- Nov -07 - Zealand Pharma Announces Financial Results for the First Nine Months of 2024
- Nov -01 - Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
- Oct -13 - GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Peptide-based Medicines
Expected Growth : 8.97 %
What the company do ?
Peptide-based medicines from Zealand Pharma A/S are innovative treatments for various diseases, leveraging peptides' unique biological properties to target specific receptors and pathways.
Why we expect these perspectives ?
Zealand Pharma A/S's peptide-based medicines growth is driven by increasing demand for novel treatments, expanding pipeline of diabetes and obesity therapies, strategic partnerships, and growing adoption in emerging markets. Additionally, the company's focus on research and development, coupled with a strong intellectual property portfolio, contributes to its 8.97% growth.
Zealand Pharma A/S Products
| Product Range | What is it ? |
|---|---|
| Lioplant | A peptide-based treatment for short bowel syndrome, which helps to reduce symptoms and improve nutritional absorption. |
| Glepaglutide | A long-acting GLP-2 analog for the treatment of short bowel syndrome, promoting intestinal growth and improving nutrient absorption. |
| Dasiglucagon | A stable and soluble glucagon analog for the treatment of severe hypoglycemia, providing rapid and effective glucose elevation. |
Zealand Pharma A/S's Porter Forces
Threat Of Substitutes
Zealand Pharma A/S has a moderate threat of substitutes due to the availability of alternative treatments for diabetes and obesity. However, the company's focus on peptide-based therapies provides some differentiation.
Bargaining Power Of Customers
Zealand Pharma A/S has a low bargaining power of customers due to the specialized nature of its products and the lack of direct competition.
Bargaining Power Of Suppliers
Zealand Pharma A/S has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Zealand Pharma A/S has a high threat of new entrants due to the growing interest in peptide-based therapies and the relatively low barriers to entry in the biotech industry.
Intensity Of Rivalry
Zealand Pharma A/S operates in a moderately competitive industry, with several established players and a growing number of new entrants.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 11.17% |
| Debt Cost | 7.35% |
| Equity Weight | 88.83% |
| Equity Cost | 7.35% |
| WACC | 7.35% |
| Leverage | 12.57% |
Zealand Pharma A/S : Quality Control
Zealand Pharma A/S passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| JAZZ | Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of … |
| CAMX.ST | Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ALK-Abelló
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
4
Camurus
A-Score
1-Year Total Return ->
5
Alkermes
A-Score
1-Year Total Return ->
6
